SK bioscience Advances Development of Next-Generation Infectious Disease Prevention Platform with Global Phase 1b CTA Submission for RSV Preventive Antibody Candidate
One daysingle sourceOne outlet reported this, once - no second voice in this corpus.
All 1 reports on Fri, 14 August 2026
What it is about
Changhyun JinMoonchel KimGyun KimJaeyong AhnGates Medical Research Institute GatesGates FoundationTerms Of ServiceAfrican Health Products Regulatory AuthorityCommunications TeamIncheon, Inch'on-Gwangyoksi, South KoreaSouth KoreaManila, Manila, Philippines
Who published it, and when
How it spread - 1 original report
Fri, 14 August 2026
1 report- manilatimes.net12:16first to report
**media[1177288]**Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 monthsCompany expands its global portfolio beyond vaccines into antibody-based preventive technologiesGrowing global R&D network strengthens capabilities in next-generation infectious disease preventionINCHEON, South Korea, Aug. 14, 2026 /PRNewswire/ -- SK bioscience announced that it has submitted a Clinical Trial Application (CTA) to the South African Health...